Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)
Clinical trial NCT02447003 · COMPLETED
Trial details
- NCT number
- NCT02447003
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-11
- Primary completion
- 2019-02-18
- Enrollment
- 254
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.